Literature DB >> 24370136

Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI.

Antonio C Westphalen1, Andrew B Rosenkrantz.   

Abstract

OBJECTIVE: In this article, we provide our perspective on current multiinstitutional efforts to improve standardization of interpretation and reporting of multiparametric prostate MRI, emphasizing their strengths and limitations based on our experiences, and provide several suggestions for guiding continued initiatives for standardizing multiparametric prostate MRI reporting.
CONCLUSION: Significant steps are being taken to facilitate the adoption of prostate MRI by urologists and other physicians in the community. Ultimately, however, prospective multicenter validation studies assessing the various aspects of a diagnostic test will be required.

Mesh:

Year:  2014        PMID: 24370136     DOI: 10.2214/AJR.13.10889

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

1.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

2.  Multiparametric magnetic resonance imaging of prostate: the evolution of a technique.

Authors:  Valdair Francisco Muglia
Journal:  Radiol Bras       Date:  2014 Sep-Oct

3.  Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.

Authors:  Daniel Junker; Michael Quentin; Udo Nagele; Michael Edlinger; Jonathan Richenberg; Georg Schaefer; Michael Ladurner; Werner Jaschke; Wolfgang Horninger; Friedrich Aigner
Journal:  World J Urol       Date:  2014-08-01       Impact factor: 4.226

4.  Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.

Authors:  Elke Hauth; Horst Hohmuth; Corina Cozub-Poetica; Stefan Bernand; Meinrad Beer; Horst Jaeger
Journal:  Br J Radiol       Date:  2015-08-13       Impact factor: 3.039

5.  MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.

Authors:  Lars Schimmöller; Michael Quentin; Christian Arsov; Andreas Hiester; Christian Buchbender; Robert Rabenalt; Peter Albers; Gerald Antoch; Dirk Blondin
Journal:  Eur Radiol       Date:  2014-06-28       Impact factor: 5.315

6.  Multiparametric MRI of the prostate: diagnostic performance and interreader agreement of two scoring systems.

Authors:  Wei-Ching Lin; Valdair F Muglia; Gyl E B Silva; Salomão Chodraui Filho; Rodolfo B Reis; Antonio C Westphalen
Journal:  Br J Radiol       Date:  2016-03-23       Impact factor: 3.039

7.  ECR 2015 Book of Abstracts - D - Satellite Symposia.

Authors: 
Journal:  Insights Imaging       Date:  2015-03

8.  False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance.

Authors:  Jeffrey S Quon; Bardia Moosavi; Maneesh Khanna; Trevor A Flood; Christopher S Lim; Nicola Schieda
Journal:  Insights Imaging       Date:  2015-05-23

Review 9.  Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy.

Authors:  Liam Toner; Mahesha Weerakoon; Damien M Bolton; Andrew Ryan; Nikolas Katelaris; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2015-10-19

Review 10.  Role of multiparametric magnetic resonance imaging in early detection of prostate cancer.

Authors:  Pieter J L De Visschere; Alberto Briganti; Jurgen J Fütterer; Pirus Ghadjar; Hendrik Isbarn; Christophe Massard; Piet Ost; Prasanna Sooriakumaran; Cristian I Surcel; Massimo Valerio; Roderick C N van den Bergh; Guillaume Ploussard; Gianluca Giannarini; Geert M Villeirs
Journal:  Insights Imaging       Date:  2016-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.